JP2011530500A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011530500A5 JP2011530500A5 JP2011521675A JP2011521675A JP2011530500A5 JP 2011530500 A5 JP2011530500 A5 JP 2011530500A5 JP 2011521675 A JP2011521675 A JP 2011521675A JP 2011521675 A JP2011521675 A JP 2011521675A JP 2011530500 A5 JP2011530500 A5 JP 2011530500A5
- Authority
- JP
- Japan
- Prior art keywords
- chlorine
- fluorine
- alkyl
- group
- further substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 45
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 45
- 239000000460 chlorine Chemical group 0.000 claims 45
- 229910052801 chlorine Inorganic materials 0.000 claims 45
- 229910052731 fluorine Inorganic materials 0.000 claims 45
- 239000011737 fluorine Chemical group 0.000 claims 45
- 125000004093 cyano group Chemical group *C#N 0.000 claims 36
- 125000000623 heterocyclic group Chemical group 0.000 claims 25
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 18
- 125000006413 ring segment Chemical group 0.000 claims 16
- 150000002431 hydrogen Chemical group 0.000 claims 12
- 125000004474 heteroalkylene group Chemical group 0.000 claims 9
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 8
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 8
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 8
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 125000002619 bicyclic group Chemical group 0.000 claims 6
- 125000004122 cyclic group Chemical group 0.000 claims 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- -1 (b) C 1 -C 6 alkyl Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8673208P | 2008-08-06 | 2008-08-06 | |
| US61/086,732 | 2008-08-06 | ||
| US22942809P | 2009-07-29 | 2009-07-29 | |
| US61/229,428 | 2009-07-29 | ||
| PCT/IB2009/053389 WO2010016005A1 (en) | 2008-08-06 | 2009-08-04 | 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011530500A JP2011530500A (ja) | 2011-12-22 |
| JP2011530500A5 true JP2011530500A5 (enExample) | 2012-09-13 |
| JP5576370B2 JP5576370B2 (ja) | 2014-08-20 |
Family
ID=41171261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011521675A Expired - Fee Related JP5576370B2 (ja) | 2008-08-06 | 2009-08-04 | Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8518952B2 (enExample) |
| EP (1) | EP2328890B1 (enExample) |
| JP (1) | JP5576370B2 (enExample) |
| AT (1) | ATE542813T1 (enExample) |
| CA (1) | CA2731368C (enExample) |
| ES (1) | ES2378513T3 (enExample) |
| WO (1) | WO2010016005A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3354650T3 (pl) | 2008-12-19 | 2022-06-13 | Vertex Pharmaceuticals Incorporated | Związki przydatne jako inhibitory kinazy atr |
| CA2755285C (en) * | 2009-03-20 | 2014-02-11 | Yunxin Y. Bo | Inhibitors of pi3 kinase |
| PH12012500778A1 (en) | 2009-10-30 | 2012-11-26 | Janssen Pharmaceutica Nv | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| EP2360158A1 (en) * | 2010-02-18 | 2011-08-24 | Almirall, S.A. | Pyrazole derivatives as jak inhibitors |
| UY33213A (es) * | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| JP5836367B2 (ja) | 2010-05-12 | 2015-12-24 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| JP2013526540A (ja) * | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| JP6115962B2 (ja) | 2011-06-27 | 2017-04-19 | ヤンセン ファーマシューティカ エヌ．ベー． | １−アリール−４−メチル−［１，２，４］トリアゾロ［４，３−ａ］キノキサリン誘導体 |
| EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
| RU2018147217A (ru) | 2011-09-30 | 2019-01-18 | Вертекс Фармасьютикалз Инкорпорейтед | Способы получения соединений, которые можно использовать в качестве ингибиторов киназы atr |
| AU2012315384B2 (en) | 2011-09-30 | 2017-08-10 | Vertex Pharmaceuticals Incorporated | Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors |
| EP2773207B1 (en) | 2011-10-31 | 2018-03-07 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
| CN104582795B (zh) | 2012-04-05 | 2018-04-20 | 沃泰克斯药物股份有限公司 | 可用作atr激酶抑制剂的化合物及其组合疗法 |
| WO2014001314A1 (en) | 2012-06-26 | 2014-01-03 | Janssen Pharmaceutica Nv | Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders |
| AU2013289284B2 (en) | 2012-07-09 | 2017-03-30 | Janssen Pharmaceutica Nv | Inhibitors of phosphodiesterase 10 enzyme |
| DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
| PH12015501130B1 (en) | 2012-11-21 | 2023-01-27 | Ptc Therapeutics Inc | Substituted reverse pyrimidine bmi-1 inhibitors |
| CN103254121B (zh) * | 2013-04-08 | 2015-08-26 | 洛阳师范学院 | 一种合成(3r,4r)-n-pg-4-甲基-3-甲胺基哌啶的方法 |
| US10584115B2 (en) * | 2013-11-21 | 2020-03-10 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine BMI-1 inhibitors |
| LT3077395T (lt) | 2013-12-05 | 2018-02-12 | Pfizer Inc. | Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai |
| US9145393B2 (en) * | 2014-01-24 | 2015-09-29 | Confluence Life Sciences, Inc. | Arylpyridinone ITK inhibitors for treating inflammation and cancer |
| BR112016026150B1 (pt) | 2014-05-09 | 2019-11-05 | Pimera, Inc. | compostos carboxílicos e seu uso na preparação de medicamentos ou composições farmacêuticas para tratar câncer |
| US9758518B2 (en) | 2015-03-04 | 2017-09-12 | Pimera, Inc. | Compositions, uses and methods for making them |
| AU2016209046A1 (en) | 2015-01-23 | 2017-07-20 | Aclaris Therapeutics, Inc. | Heterocyclic ITK inhibitors for treating inflammation and cancer |
| CA2984183C (en) | 2015-05-01 | 2021-11-09 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof |
| CN105130991B (zh) * | 2015-07-10 | 2017-09-19 | 成都知普莱生物医药科技有限公司 | 一种合成骨形态发生蛋白受体抑制剂的方法 |
| US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| MX383747B (es) | 2016-02-24 | 2025-03-14 | Pfizer | Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de quinasas janus (jak) |
| WO2018140648A1 (en) | 2017-01-25 | 2018-08-02 | Eric Jon Jacobsen | Pyrrolopyrimidine itk inhibitors for treating inflammation and cancer |
| JP2020512975A (ja) | 2017-03-28 | 2020-04-30 | ピメラ，インク． | Ｐｏｌ１阻害剤の新規な結晶形態 |
| CN107056681B (zh) * | 2017-03-30 | 2019-10-01 | 广州白云山光华制药股份有限公司 | 一种托法替布中间体的制备方法 |
| WO2019034973A1 (en) | 2017-08-14 | 2019-02-21 | Pfizer Inc. | PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES |
| CN107474047B (zh) * | 2017-08-29 | 2019-10-29 | 浙江工业大学 | 1,2,4-三唑并杂环类化合物的合成方法 |
| CN107827811B (zh) * | 2017-11-15 | 2021-01-29 | 上海皓伯化工科技有限公司 | 一种制备n-取代-1,2,3,6-四氢吡啶的方法 |
| JP2021151955A (ja) * | 2018-05-22 | 2021-09-30 | 株式会社カネカ | 光学活性−ｃｉｓ−アミノピペリジンの製造方法 |
| JP7478142B2 (ja) * | 2018-06-07 | 2024-05-02 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１阻害剤 |
| EP3801503A4 (en) | 2018-06-07 | 2021-12-08 | Disarm Therapeutics, Inc. | INHIBITORS OF SARM1 |
| EP3608326A1 (en) | 2018-08-10 | 2020-02-12 | Irbm S.P.A. | Tricyclic inhibitors of hepatitis b virus |
| JP2021535198A (ja) | 2018-08-17 | 2021-12-16 | ピーティーシー セラピューティクス， インコーポレイテッド | 膵臓癌を治療する方法 |
| UY38705A (es) | 2019-05-23 | 2020-12-31 | Irbm S P A | Inhibidores tricíclicos sustituidos con oxalamido del virus de hepatitis b |
| EP3825318A1 (en) | 2019-11-25 | 2021-05-26 | Promidis S.r.l. | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus |
| EP3741762A1 (en) | 2019-05-23 | 2020-11-25 | Irbm S.P.A. | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus |
| IL298941A (en) | 2020-06-11 | 2023-02-01 | Chdi Foundation Inc | Heterocyclic compounds and imaging agents for the imaging of huntingtin protein |
| WO2022026935A1 (en) * | 2020-07-31 | 2022-02-03 | Children's Hospital Medical Center | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof |
| KR102473645B1 (ko) * | 2020-08-28 | 2022-12-05 | (주)부흥산업사 | (2S,5R)-벤질 5-(t-부톡시카르보닐아미노)-2-메틸피페리딘-1-카르복실레이트의 제조방법 |
| JP2024529453A (ja) * | 2021-07-30 | 2024-08-06 | チルドレンズ ホスピタル メディカル センター | 多環式ｉｒａｋ及びｆｌｔ３阻害化合物並びにその使用 |
| AU2023283393A1 (en) * | 2022-06-10 | 2025-01-02 | Interline Therapeutics, Inc. | Imidazo(1,2-a)pyridine derivatives as ripk2 inhibitors |
| AR129535A1 (es) | 2022-06-21 | 2024-09-04 | Syngenta Crop Protection Ag | Derivados de carboxamida heterocíclicos bicíclicos microbiocidas |
| EP4608836A1 (en) | 2022-10-27 | 2025-09-03 | Syngenta Crop Protection AG | Microbiocidal heterobicyclic dihydrooxadiazine derivatives |
| CN116478076A (zh) * | 2023-04-26 | 2023-07-25 | 南京优氟医药科技有限公司 | 一种(2s,4s)-1-叔丁氧羰基-2-(二氟甲基)-4-羟基吡咯烷的制备方法 |
| WO2026006247A1 (en) * | 2024-06-26 | 2026-01-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | 2-(piperidin-3-yl)isoindole-1,3-dione analogs and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| GB9722320D0 (en) | 1997-10-22 | 1997-12-17 | Janssen Pharmaceutica Nv | Human cell cycle checkpoint proteins |
| US6383744B1 (en) | 1998-07-10 | 2002-05-07 | Incyte Genomics, Inc. | Human checkpoint kinase |
| EP1135135A4 (en) | 1998-09-18 | 2006-08-09 | Smithkline Beecham Corp | CHK1 KINASE INHIBITORS |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| JP4652648B2 (ja) | 1999-08-27 | 2011-03-16 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | キメラアンチセンスオリゴヌクレオチド、およびその細胞トランスフェクション処方物 |
| DE60019318T2 (de) | 1999-09-22 | 2006-03-09 | Canbas Co., Ltd., Numazu | Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe |
| US6211164B1 (en) | 2000-03-10 | 2001-04-03 | Abbott Laboratories | Antisense oligonucleotides of the human chk1 gene and uses thereof |
| NZ527302A (en) | 2001-01-05 | 2006-10-27 | Abgenix Inc | Antibodies to insulin-like growth factor I receptor |
| UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| AU2003234464B2 (en) * | 2002-05-03 | 2009-06-04 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| EA009337B1 (ru) | 2003-01-09 | 2007-12-28 | Пфайзер Инк. | Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии |
| DK1641780T3 (da) | 2003-06-24 | 2009-02-02 | Pfizer Prod Inc | Fremgangsmåder til fremstilling af 1-[(benzimidazol-1yl)quinolin-8-yl]-piperidin-4-ylamin-derivater |
| US20080070930A1 (en) * | 2006-08-24 | 2008-03-20 | Huang Kenneth H | Pyrimidine and Pyrazine Derivatives |
| JP2011500806A (ja) | 2007-10-25 | 2011-01-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
-
2009
- 2009-08-04 JP JP2011521675A patent/JP5576370B2/ja not_active Expired - Fee Related
- 2009-08-04 EP EP09786799A patent/EP2328890B1/en not_active Not-in-force
- 2009-08-04 CA CA2731368A patent/CA2731368C/en not_active Expired - Fee Related
- 2009-08-04 US US13/057,558 patent/US8518952B2/en not_active Expired - Fee Related
- 2009-08-04 WO PCT/IB2009/053389 patent/WO2010016005A1/en not_active Ceased
- 2009-08-04 AT AT09786799T patent/ATE542813T1/de active
- 2009-08-04 ES ES09786799T patent/ES2378513T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014140739A (ru) | Соединения на основе имидазо[1, 2-b]пиридазина, композиции таких соединений и способы их применения | |
| NO20084742L (no) | Aziridinyl-epotilonforbindelser | |
| CA2565660A1 (en) | Ortho substituted aryl or heteroaryl amide compounds | |
| JO2643B1 (en) | Derivatives of 2-aryl-6-phenylimidazole [a-1,2] pyridine, their preparation and therapeutic use | |
| CA2536870A1 (en) | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists | |
| EA201171328A1 (ru) | Производное замещенного изохинолина | |
| JP2013531029A5 (enExample) | ||
| WO2003080580A3 (en) | Quinoline derivatives and their use as 5-ht6 ligands | |
| JP2017137291A5 (enExample) | ||
| JP2016518434A5 (enExample) | ||
| WO2005105732A8 (en) | Substituted methyl aryl or heteroaryl amide compounds | |
| HRP20080113T3 (hr) | Supstituirani piridinilni i pirimidinilni derivati kao modulatori metabolizma i liječenje bolesti koje su s tim povezane | |
| JP2017535614A5 (enExample) | ||
| RU2009146124A (ru) | Дигидрохиноновые и дигидронафтиридиновые ингибиторы киназы jnk | |
| AR086144A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| JP2010280669A5 (enExample) | ||
| JP2010506854A5 (enExample) | ||
| JP2006524660A5 (enExample) | ||
| GB201201744D0 (en) | Novel compounds | |
| NO20080738L (no) | Fremgangsmater for neurobeskyttelse | |
| TW200635585A (en) | Monocyclic substituted methanones | |
| AR063804A1 (es) | Compuestos de azoniabiciclo[2.2.2]octano | |
| EA200870321A1 (ru) | Способ получения 4-оксохинолинового соединения | |
| RU2013125326A (ru) | Гетероциклические соединения в качестве зондов для визуализации tau-патологии | |
| WO2008136444A1 (ja) | 縮合複素環誘導体 |